Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,163 matching trials from the live ClinicalTrials.gov search.
Conditions
Hepatitis C
Interventions
TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
Conditions
Weight
Interventions
LIPO-102, LIPO-102 Low, LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
San Diego, California • New York, New York
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Acute Stroke, Ischemic Stroke, Stroke
Interventions
Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection
Drug · Other
Lead sponsor
DiaMedica Therapeutics Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
36
States / cities
Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more
Completed Phase 4 Interventional Results available

Management of Superficial Thrombophlebitis

NCT00264381
Conditions
Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
Interventions
Dalteparin sodium injection
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Conditions
Hereditary Angioedema (HAE)
Interventions
Recombinant human C1 esterase inhibitor, Placebo, SHP623
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
Obesity
Interventions
ABBV-295, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Active, not recruiting Phase 3 Interventional Results available

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790
Conditions
Polycythemia Vera
Interventions
Rusfertide, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
80
States / cities
Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
Conditions
Menopause, Aging
Interventions
KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Osteoarthritis
Interventions
Placebo, gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD)
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more
Conditions
Myositis, Interstitial Lung Disease
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
70
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Completed Phase 4 Interventional Results available

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070
Conditions
Sarcoidosis, Pulmonary
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 39 more
Conditions
Arthritis, Rheumatoid
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
Conditions
Gout
Interventions
Rilonacept, Placebo (for Rilonacept)
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
San Diego, California • Santa Maria, California • Whittier, California + 30 more
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Phoenix, Arizona • Sun City, Arizona • Encino, California + 14 more
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

NCT00387621
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Placebo, Saline
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more